Condition category
Mental and Behavioural Disorders
Date applied
11/07/2013
Date assigned
16/08/2013
Last edited
18/09/2017
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
The aim of this study is to find out about the effect of Cannabidiol (CBD) on brain function. CBD comes from the cannabis plant, but does not produce a 'high' as its effects in humans are almost undetectable except for mild sedation at high doses. The researchers want to learn more about the effect of CBD on the human mind in a simulated version of everyday life.

Who can participate?
People who are currently attending the OASIS clinic who are not currently taking any psychiatric mediation, aged between 18 and 50, who are physically well, with no history of major illness.

What does the study involve?
The study involves two blocks of 5 days each. On day 1 of each block participants are given a capsule containing either CBD or placebo (dummy) in a random order. They are then given a box containing the remaining doses, and are asked to take a dose of CBD in the evenings for the next 3 days. On the 5th day of each block participants have the experimental session, where a small blood sample is taken to test how much CBD is in their body. They are then be asked to complete some questionnaires and finally complete the virtual-reality bus ride, followed by a simulated public-speaking task. Their heart rate is measured and small saliva samples are taken. The CBD week results are compared with the placebo week results.

What are the possible benefits and risks of participating?
Participants are paid £28 per day they are involved in the study, which is 10 days in total giving a maximum of £280. They are collected from home by taxi and dropped back home at the end of each day. Some people may experience mild sedation after taking CBD, so participants are asked not to drive, operate heavy machinery or engage in hazardous activities during the days they take any capsules. There are no documented effects of CBD on the heart or the nervous system aside from mild sedation, and no adverse effects have been recorded. It can very occasionally happen that some people experience a degree of nausea or disturbances in their vision after being in the virtual reality. Therefore if at any time they wish to stop, they can stop immediately.

Where is the study run from?
Institute of Psychiatry, King's College London (UK)

When is study starting and how long is it expected to run for?
July 2013 to August 2015

Who is funding the study?
The study is funded by an unrestricted grant from GW Pharma (UK)

Who is the main contact?
Dr Paul Morrison
paul.morrison@kcl.ac.uk

Trial website

Contact information

Type

Scientific

Primary contact

Dr Paul Morrison

ORCID ID

Contact details

M5.06.02 Psychosis Studies
5th Floor
Main Building
Institute of Psychiatry
16 DeCrespigny Park
London
SE5 8AF
United Kingdom
+44 (0)207 848 0057
paul.morrison@kcl.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

3.2d30.5.13

Study information

Scientific title

The effect of Cannabidiol (CBD) on paranoid cognitions in humans: a randomised controlled trial

Acronym

CBD VR2

Study hypothesis

CBD decreases perceived social threat and their endocrine sequelae.

Ethics approval

National Research Ethics Service (NRES) Committee London, 30/05/2013

Study design

Randomised cross-over design

Primary study design

Interventional

Secondary study design

Randomised cross over trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet

Condition

Paranoid cognitions

Intervention

All participants will receive Cannabidiol (CBD) on one occasion, and placebo on the other. The order of administrations will be randomised and double-blinded. The drugs will be administered as oral capsules, 3 x 100 mg being taken twice a day (total dose per day is 600 mg).

Intervention type

Drug

Phase

Not Applicable

Drug names

Cannabidiol

Primary outcome measures

1. Autonomic arousal using pulse and respiratory rates and saliva swabs to measure cortisol
2. Paranoid thinking using the State-Social Paranoid Scale and the Cape-(state version)
3. Affective processing using the Beck Anxiety Inventory, the Bond and Lader Visual Analogue Scale and the Negative-Self-Statement-Scale

Secondary outcome measures

Cognitive functioning using the Letter-Number-Span to measure working memory, and the Hopkins-Verbal-Learning-Task-Revised

Overall trial start date

22/07/2013

Overall trial end date

22/08/2015

Reason abandoned

Eligibility

Participant inclusion criteria

1. Aged 18-50 years
2. English as first language
3. Patient at OASIS service

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

20

Participant exclusion criteria

1. Subjects who have been diagnosed with a major mental or physical illness (epilepsy, schizophrenia, bipolar disorder)
2. Subjects must not have had previous treatment with antipsychotic or mood stabilising drugs
3. Pregnancy
4. Drug/alcohol dependence

Recruitment start date

22/07/2013

Recruitment end date

01/01/2015

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Institute of Psychiatry
London
SE5 8AF
United Kingdom

Sponsor information

Organisation

King's College London (UK)

Sponsor details

Institute of Psychiatry
16 DeCrespigny Park
London
SE5 8AF
United Kingdom

Sponsor type

University/education

Website

http://www.kcl.ac.uk/iop/index.aspx

Funders

Funder type

Industry

Funder name

GW Pharmaceuticals (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

18/09/2017: No publications found, verifying study status with principal investigator.